The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 56)
Therapeutic Pipeline Program, 2017
The notion of misfolded alpha-synuclein (alpha-syn) aggregates moving from neuron-to-neuron is a mechanism that is gaining widespread acceptance as a central mechanism in the development of Parkinson's disease. Therapies designed to stop this spreading point towards a novel therapeutic route for preventing the development of Parkinson's disease.
With the development of...
Research Grant, 2017
Promising Outcomes of Original Grant:
Funding from The Michael J. Fox Foundation (MJFF) has facilitated the rapid screening of over 370,000 compounds of chemicals that prevent alpha-synuclein (protein that clumps in the brains of those with Parkinson's) accumulation. At the end of the original grant period, we identified three chemical compounds that could specifically reduce alpha-synuclein accumu...
LRRK2 Biology Consortium, 2017
Parkinson's disease (PD) mutations in the LRRK2 protein have been linked to decreased GTPase (enzyme that binds to G proteins) activity and increased kinase (enzyme that modifies a protein) activity. Many LRRK2-specific brain-penetrant kinase inhibitors have been developed but many have major side effects. In addition, different PD-linked LRRK2 mutations likely have different effe...
Target Advancement Program, 2016
Brain cells use surveillance mechanisms to get rid of toxic proteins, such as mutant alpha-synuclein, that otherwise would accumulate and kill them. We have previously identified that one of such surveillance/cleaning mechanisms fails in brain cells affected by Parkinson's disease. In this study we intend to test whether activating this failing pathway in Parkins...
Therapeutic Pipeline Program, 2016
The hypothesis that misfolded alpha-synuclein (a protein associated with Parkinson's) aggregates (clumps) move from neuron-to-neuron is gaining widespread acceptance as a central mechanism in the development of Parkinson's disease (PD). Therapies designed to stop this spreading point towards a novel therapeutic route for preventing the development of PD.
With the devel...
Researchers: Edward A. Fon, MD, FRCP(C)